Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced positive results from Phase 1 studies of CDX-1307 in patients with advanced epithelial cancers ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE